A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Full Text View - ClinicalTrials.gov

Full Text View

 This study is not yet open for participant recruitment. 

Purpose

The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy.

Responsible Party:	Janssen Research & Development, LLC
ClinicalTrials.gov Identifier:	NCT01846611     History of Changes
Other Study ID Numbers:	CR100983, ET743OVC3006, 2012-004808-34
Study First Received:	May 1, 2013
Last Updated:	May 1, 2013
Health Authority:	United States: Food and Drug Administration Australia: National Health and Medical Research Council New Zealand: Ministry of Health China: Food and Drug Administration Switzerland: Federal Office of Public Health Israel: Israeli Health Ministry Pharmaceutical Administration South Africa: Medicines Control Council United Kingdom: Medicines and Healthcare Products Regulatory Agency Russia: Pharmacological Committee, Ministry of Health